{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:52:22Z","timestamp":1793731942872,"version":"4.6.1"},"reference-count":126,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,11,28]],"date-time":"2016-11-28T00:00:00Z","timestamp":1480291200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s11239-016-1446-0","type":"journal-article","created":{"date-parts":[[2016,11,28]],"date-time":"2016-11-28T16:33:10Z","timestamp":1480350790000},"page":"365-379","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":121,"title":["Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation"],"prefix":"10.1007","volume":"43","author":[{"given":"Andreas","family":"Zirlik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Bode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,28]]},"reference":[{"key":"1446_CR1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1543-5946(03)90001-8","volume":"1","author":"AH Abdelhafiz","year":"2003","unstructured":"Abdelhafiz AH, Wheeldon NM (2003) Use of resources and cost implications of stroke prophylaxis with warfarin for patients with nonvalvular atrial fibrillation. Am J Geriatr Pharmacother 1:53\u201360","journal-title":"Am J Geriatr Pharmacother"},{"key":"1446_CR2","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","volume":"367","author":"ACTIVE Writing Group of the ACTIVE Investigators","year":"2006","unstructured":"ACTIVE Writing Group of the ACTIVE Investigators (2006) Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with Irbesartan for prevention of vascular events (ACTIVE W): a randomised controlled trial. The Lancet 367:1903\u20131912","journal-title":"The Lancet"},{"key":"1446_CR3","doi-asserted-by":"crossref","first-page":"e44S","DOI":"10.1378\/chest.11-2292","volume":"141","author":"W Ageno","year":"2012","unstructured":"Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G (2012) Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 141:e44S\u2013e88S","journal-title":"Chest"},{"key":"1446_CR4","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3111\/13696998.2015.1007210","volume":"18","author":"A Amin","year":"2015","unstructured":"Amin A, Bruno A, Trocio J, Lin J, Lingohr-Smith M (2015) Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs. warfarin or placebo in the US. J Med Econ 18:399\u2013409","journal-title":"J Med Econ"},{"key":"1446_CR5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejim.2008.04.005","volume":"20","author":"P Amouyel","year":"2009","unstructured":"Amouyel P, Mismetti P, Langkilde LK, Jasso-Mosqueda G, Nelander K, Lamarque H (2009) INR variability in atrial fibrillation: a risk model for cerebrovascular events. Eur J Intern Med 20:63\u201369","journal-title":"Eur J Intern Med"},{"key":"1446_CR6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11239-006-9022-7","volume":"23","author":"J Ansell","year":"2007","unstructured":"Ansell J, Hollowell J, Pengo V, Martinez-Brotons F, Caro J, Drouet L (2007) Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM). J Thromb Thrombolysis 23:83\u201391","journal-title":"J Thromb Thrombolysis"},{"key":"1446_CR7","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1056\/NEJMc1411800","volume":"371","author":"JE Ansell","year":"2014","unstructured":"Ansell JE, Bakhru SH, Laulicht BE et al (2014) Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med 371:2141\u20132142","journal-title":"N Engl J Med"},{"key":"1446_CR8","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1093\/eurheartj\/eht499","volume":"35","author":"L Azoulay","year":"2014","unstructured":"Azoulay L, Dell\u2019aniello S, Simon TA, Renoux C, Suissa S (2014) Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes. Eur Heart J 35:1881\u20131887","journal-title":"Eur Heart J"},{"key":"1446_CR9","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ijcard.2013.10.062","volume":"170","author":"MC Bahit","year":"2013","unstructured":"Bahit MC, Lopes RD, Wojdyla DM et al (2013) Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial. Int J Cardiol 170:215\u2013220","journal-title":"Int J Cardiol"},{"key":"1446_CR10","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.ahj.2015.07.006","volume":"170","author":"S Bansilal","year":"2015","unstructured":"Bansilal S, Bloomgarden Z, Halperin JL et al (2015) Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF Trial). Am Heart J 170:675\u2013682","journal-title":"Am Heart J"},{"key":"1446_CR11","unstructured":"Bayer Pharma AG (2016) Xarelto\u00ae (rivaroxaban) Summary of Product Characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000944\/WC500057108.pdf . Accessed 21 Sept 2016"},{"key":"1446_CR12","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1160\/TH14-06-0484","volume":"113","author":"J Beyer-Westendorf","year":"2015","unstructured":"Beyer-Westendorf J, Ageno W (2015) Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism. Thromb Haemost 113:231\u2013246","journal-title":"Thromb Haemost"},{"key":"1446_CR13","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1160\/TH14-11-0954","volume":"113","author":"J Beyer-Westendorf","year":"2015","unstructured":"Beyer-Westendorf J, Ebertz F, F\u00f6rster K et al (2015) Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost 113:1247\u20131257","journal-title":"Thromb Haemost"},{"key":"1446_CR14","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1093\/europace\/euv421","volume":"18","author":"J Beyer-Westendorf","year":"2016","unstructured":"Beyer-Westendorf J, Ehlken B, Evers T (2016) Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation. Europace 18:1150\u20131157","journal-title":"Europace"},{"key":"1446_CR15","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/europace\/euu319","volume":"17","author":"J Beyer-Westendorf","year":"2015","unstructured":"Beyer-Westendorf J, F\u00f6rster K, Ebertz F et al (2015) Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry. Europace 17:530\u2013538","journal-title":"Europace"},{"key":"1446_CR16","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1182\/blood-2014-03-563577","volume":"124","author":"J Beyer-Westendorf","year":"2014","unstructured":"Beyer-Westendorf J, F\u00f6rster K, Pannach S et al (2014) Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood 124:955\u2013962","journal-title":"Blood"},{"key":"1446_CR17","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/bcp.12391","volume":"78","author":"J Beyer-Westendorf","year":"2014","unstructured":"Beyer-Westendorf J, Gelbricht V, Forster K et al (2014) Safety of switching from vitamin-K antagonists to dabigatran or rivaroxaban in daily care\u2014results from the Dresden NOAC registry. Br J Clin Pharmacol 78:908\u2013917","journal-title":"Br J Clin Pharmacol"},{"key":"1446_CR18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/jth.12973","volume":"13","author":"J Beyer-Westendorf","year":"2015","unstructured":"Beyer-Westendorf J, Werth S, Tittl L, Michalski F, Marten S, Weiss N (2015) Real life efficacy and safety of apixaban for stroke prevention in atrial fibrillation\u2014results of the prospective NOAC registry (NCT01588119). J Thromb Haemost 13:35 (abstract AS098)","journal-title":"J Thromb Haemost"},{"key":"1446_CR19","doi-asserted-by":"crossref","first-page":"472","DOI":"10.7326\/0003-4819-154-7-201104050-00005","volume":"154","author":"HE Bloomfield","year":"2011","unstructured":"Bloomfield HE, Krause A, Greer N et al (2011) Meta-analysis: effect of patient self-testing and self-management of long-term anticoagulation on major clinical outcomes. Ann Intern Med 154:472\u2013482","journal-title":"Ann Intern Med"},{"key":"1446_CR20","unstructured":"Boehringer Ingelheim International GmbH (2016) Pradaxa\u00ae (dabigatran etexilate) Summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000829\/WC500041059.pdf . Accessed 21 Sept 2016"},{"key":"1446_CR21","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ijcard.2015.05.141","volume":"196","author":"M Brambatti","year":"2015","unstructured":"Brambatti M, Darius H, Oldgren J et al (2015) Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: results from the RE-LY trial. Int J Cardiol 196:127\u2013131","journal-title":"Int J Cardiol"},{"key":"1446_CR22","unstructured":"Bristol-Myers Squibb, Pfizer (2016) Eliquis\u00ae (apixaban) Summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002148\/WC500107728.pdf . Accessed 21 Sept 2016"},{"key":"1446_CR23","doi-asserted-by":"crossref","first-page":"304","DOI":"10.4065\/mcp.2010.0575","volume":"86","author":"MT Brown","year":"2011","unstructured":"Brown MT, Bussell JK (2011) Medication adherence: WHO cares? Mayo Clin Proc 86:304\u2013314","journal-title":"Mayo Clin Proc"},{"key":"1446_CR24","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1056\/NEJMsa1103053","volume":"365","author":"DS Budnitz","year":"2011","unstructured":"Budnitz DS, Lovegrove MC, Shehab N, Richards CL (2011) Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 365:2002\u20132012","journal-title":"N Engl J Med"},{"key":"1446_CR25","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1007\/s40265-015-0508-5","volume":"75","author":"CB Burness","year":"2015","unstructured":"Burness CB (2015) Idarucizumab: first global approval. Drugs 75:2155\u20132161","journal-title":"Drugs"},{"key":"1446_CR26","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/eurheartj\/ehv466","volume":"37","author":"AJ Camm","year":"2016","unstructured":"Camm AJ, Amarenco P, Haas S et al (2016) XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J 37:1145\u20131153","journal-title":"Eur Heart J"},{"key":"1446_CR27","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","volume":"33","author":"AJ Camm","year":"2012","unstructured":"Camm AJ, Lip GYH, De Caterina R et al (2012) 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European heart rhythm association. Eur Heart J 33:2719\u20132747","journal-title":"Eur Heart J"},{"key":"1446_CR28","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/europace\/eus305","volume":"14","author":"AJ Camm","year":"2012","unstructured":"Camm AJ, Lip GYH, De Caterina R et al (2012) 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European heart rhythm association. Europace 14:1385\u20131413","journal-title":"Europace"},{"key":"1446_CR29","first-page":"493","volume":"161","author":"JJ Caro","year":"1999","unstructured":"Caro JJ, Flegel KM, Orejuela ME, Kelley HE, Speckman JL, Migliaccio-Walle K (1999) Anticoagulant prophylaxis against stroke in atrial fibrillation: effectiveness in actual practice. CMAJ 161:493\u2013497","journal-title":"CMAJ"},{"key":"1446_CR30","doi-asserted-by":"crossref","first-page":"h1585","DOI":"10.1136\/bmj.h1585","volume":"350","author":"HY Chang","year":"2015","unstructured":"Chang HY, Zhou M, Tang W, Alexander GC, Singh S (2015) Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study. BMJ 350:h1585","journal-title":"BMJ"},{"key":"1446_CR31","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ijcard.2015.03.369","volume":"191","author":"CH Chen","year":"2015","unstructured":"Chen CH, Chen MC, Gibbs H et al (2015) Antithrombotic treatment for stroke prevention in atrial fibrillation: the Asian agenda. Int J Cardiol 191:244\u2013253","journal-title":"Int J Cardiol"},{"key":"1446_CR32","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139\u20131151","journal-title":"N Engl J Med"},{"key":"1446_CR33","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMc1007378","volume":"363","author":"SJ Connolly","year":"2010","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L (2010) Newly identified events in the RE-LY trial. N Engl J Med 363:1875\u20131876","journal-title":"N Engl J Med"},{"key":"1446_CR34","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJMc1407908","volume":"371","author":"SJ Connolly","year":"2014","unstructured":"Connolly SJ, Wallentin L, Yusuf S (2014) Additional events in the RE-LY trial. N Engl J Med 371:1464\u20131465","journal-title":"N Engl J Med"},{"key":"1446_CR35","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3810\/pgm.2014.11.2829","volume":"126","author":"J Costin","year":"2014","unstructured":"Costin J, Ansell J, Laulicht B, Bakhru S, Steiner S (2014) Reversal agents in development for the new oral anticoagulants. Postgrad Med 126:19\u201324","journal-title":"Postgrad Med"},{"key":"1446_CR36","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","volume":"11","author":"JA Cramer","year":"2008","unstructured":"Cramer JA, Roy A, Burrell A et al (2008) Medication compliance and persistence: terminology and definitions. Value Health 11:44\u201347","journal-title":"Value Health"},{"key":"1446_CR37","first-page":"1889","volume":"9","author":"C Crivera","year":"2015","unstructured":"Crivera C, Nelson WW, Bookhart B et al (2015) Pharmacy quality alliance measure: adherence to non-warfarin oral anticoagulant medication. Circ Cardiovasc Qual Outcomes 9:1889\u20131895 (abstract A366)","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"1446_CR38","unstructured":"Daiichi Sankyo Europe GmbH (2016) Lixiana\u00ae (edoxaban) Summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002629\/WC500189045.pdf . Accessed 21 Sept 2016"},{"key":"1446_CR39","unstructured":"Daiichi Sankyo Inc (2015) Savaysa\u00ae (edoxaban) Prescribing Information. http:\/\/dsi.com\/prescribing-information-portlet\/getPIContent?productName=Savaysa&inline=true . Accessed 21 Sept 2016"},{"key":"1446_CR40","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.amjmed.2012.01.033","volume":"125","author":"J Donz\u00e9","year":"2012","unstructured":"Donz\u00e9 J, Clair C, Hug B et al (2012) Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am J Med 125:773\u2013778","journal-title":"Am J Med"},{"key":"1446_CR41","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0009-9236(03)00015-8","volume":"73","author":"AW Dreisbach","year":"2003","unstructured":"Dreisbach AW, Japa S, Gebrekal AB et al (2003) Cytochrome P4502C9 activity in end-stage renal disease. Clin Pharmacol Ther 73:475\u2013477","journal-title":"Clin Pharmacol Ther"},{"key":"1446_CR42","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","volume":"369","author":"JW Eikelboom","year":"2013","unstructured":"Eikelboom JW, Connolly SJ, Brueckmann M et al (2013) Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 369:1206\u20131214","journal-title":"N Engl J Med"},{"key":"1446_CR43","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.110.004747","volume":"123","author":"JW Eikelboom","year":"2011","unstructured":"Eikelboom JW, Wallentin L, Connolly SJ et al (2011) Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 123:2363\u20132372","journal-title":"Circulation"},{"key":"1446_CR44","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1161\/CIRCULATIONAHA.109.853119","volume":"121","author":"JW Eikelboom","year":"2010","unstructured":"Eikelboom JW, Weitz JI (2010) New anticoagulants. Circulation 121:1523\u20131532","journal-title":"Circulation"},{"key":"1446_CR45","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/ehjcvp\/pvu024","volume":"1","author":"JA Ezekowitz","year":"2015","unstructured":"Ezekowitz JA, Lewis BS, Lopes RD et al (2015) Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. Eur Heart J Cardiovas Pharmacother 1:86\u201394","journal-title":"Eur Heart J Cardiovas Pharmacother"},{"key":"1446_CR46","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.ahj.2009.02.005","volume":"157","author":"MD Ezekowitz","year":"2009","unstructured":"Ezekowitz MD, Connolly S, Parekh A et al (2009) Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J 157:805\u2013810","journal-title":"Am Heart J"},{"key":"1446_CR47","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCOUTCOMES.110.937680","volume":"3","author":"MC Fang","year":"2010","unstructured":"Fang MC, Go AS, Chang Y et al (2010) Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ Cardiovasc Qual Outcomes 3:624\u2013631","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"1446_CR48","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nrcardio.2014.222","volume":"12","author":"J Fareed","year":"2015","unstructured":"Fareed J (2015) Antithrombotic therapy in 2014: making headway in anticoagulant and antiplatelet therapy. Nat Rev Cardiol 12:70\u201371","journal-title":"Nat Rev Cardiol"},{"key":"1446_CR49","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/eurjhf\/hft111","volume":"15","author":"J Ferreira","year":"2013","unstructured":"Ferreira J, Ezekowitz MD, Connolly SJ et al (2013) Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial. Eur J Heart Fail 15:1053\u20131061","journal-title":"Eur J Heart Fail"},{"key":"1446_CR50","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1093\/eurheartj\/ehr342","volume":"32","author":"KAA Fox","year":"2011","unstructured":"Fox KAA, Piccini JP, Wojdyla D et al (2011) Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 32:2387\u20132394","journal-title":"Eur Heart J"},{"key":"1446_CR51","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1365-2125.2012.04369.x","volume":"75","author":"C Frost","year":"2013","unstructured":"Frost C, Wang J, Nepal S et al (2013) Apixaban, an oral, direct Factor Xa inhibitor: single-dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol 75:476\u2013487","journal-title":"Br J Clin Pharmacol"},{"key":"1446_CR52","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E et al (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369:2093\u20132104","journal-title":"N Engl J Med"},{"key":"1446_CR53","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1161\/STROKEAHA.108.516344","volume":"40","author":"DJ Gladstone","year":"2009","unstructured":"Gladstone DJ, Bui E, Fang J et al (2009) Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke 40:235\u2013240","journal-title":"Stroke"},{"key":"1446_CR54","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1056\/NEJMoa1311376","volume":"370","author":"DJ Gladstone","year":"2014","unstructured":"Gladstone DJ, Spring M, Dorian P et al (2014) Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med 370:2467\u20132477","journal-title":"N Engl J Med"},{"key":"1446_CR55","doi-asserted-by":"crossref","first-page":"E121","DOI":"10.1503\/cmaj.121218","volume":"185","author":"T Gomes","year":"2013","unstructured":"Gomes T, Mamdani MM, Holbrook AM, Paterson JM, Hellings C, Juurlink DN (2013) Rates of hemorrhage during warfarin therapy for atrial fibrillation. CMAJ 185:E121\u2013E127","journal-title":"CMAJ"},{"key":"1446_CR56","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1001\/archinternmed.2012.4485","volume":"172","author":"T Gomes","year":"2012","unstructured":"Gomes T, Mamdani MM, Holbrook AM, Paterson JM, Juurlink DN (2012) Persistence with therapy among patients treated with warfarin for atrial fibrillation. Arch Intern Med 172:1687\u20131689","journal-title":"Arch Intern Med"},{"key":"1446_CR57","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/jth.12845","volume":"13","author":"A Gorst-Rasmussen","year":"2015","unstructured":"Gorst-Rasmussen A, Skjoth F, Larsen TB, Rasmussen LH, Lip GYH, Lane DA (2015) Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study. J Thromb Haemost 13:495\u2013504","journal-title":"J Thromb Haemost"},{"key":"1446_CR58","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981\u2013992","journal-title":"N Engl J Med"},{"key":"1446_CR59","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/bcpt.12084","volume":"113","author":"L Gschwind","year":"2013","unstructured":"Gschwind L, Rollason V, Daali Y, Bonnabry P, Dayer P, Desmeules JA (2013) Role of P-glycoprotein in the uptake\/efflux transport of oral vitamin K antagonists and rivaroxaban through the Caco-2 cell model. Basic Clin Pharmacol Toxicol 113:259\u2013265","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"1446_CR60","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1161\/CIRCULATIONAHA.113.005008","volume":"130","author":"JL Halperin","year":"2014","unstructured":"Halperin JL, Hankey GJ, Wojdyla DM et al (2014) Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation 130:138\u2013146","journal-title":"Circulation"},{"key":"1446_CR61","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1093\/eurheartj\/ehu046","volume":"35","author":"S Halvorsen","year":"2014","unstructured":"Halvorsen S, Atar D, Yang H et al (2014) Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J 35:1864\u20131872","journal-title":"Eur Heart J"},{"key":"1446_CR62","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1161\/CIRCULATIONAHA.110.004424","volume":"123","author":"GJ Hankey","year":"2011","unstructured":"Hankey GJ, Eikelboom JW (2011) Dabigatran etexilate: a new oral thrombin inhibitor. Circulation 123:1436\u20131450","journal-title":"Circulation"},{"key":"1446_CR63","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S1474-4422(12)70042-X","volume":"11","author":"GJ Hankey","year":"2012","unstructured":"Hankey GJ, Patel MR, Stevens SR et al (2012) Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol 11:315\u2013322","journal-title":"Lancet Neurol"},{"key":"1446_CR64","doi-asserted-by":"crossref","first-page":"492","DOI":"10.7326\/0003-4819-131-7-199910050-00003","volume":"131","author":"RG Hart","year":"1999","unstructured":"Hart RG, Benavente O, McBride R, Pearce LA (1999) Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 131:492\u2013501","journal-title":"Ann Intern Med"},{"key":"1446_CR65","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","volume":"146","author":"RG Hart","year":"2007","unstructured":"Hart RG, Pearce LA, Aguilar MI (2007) Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146:857\u2013867","journal-title":"Ann Intern Med"},{"key":"1446_CR66","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/europace\/euv309","volume":"17","author":"H Heidbuchel","year":"2015","unstructured":"Heidbuchel H, Verhamme P, Alings M et al (2015) Updated European heart rhythm association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 17:1467\u20131507","journal-title":"Europace"},{"key":"1446_CR67","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/europace\/eut083","volume":"15","author":"H Heidbuchel","year":"2013","unstructured":"Heidbuchel H, Verhamme P, Alings M et al (2013) European heart rhythm association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 15:625\u2013651","journal-title":"Europace"},{"key":"1446_CR68","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1161\/CIRCULATIONAHA.113.003628","volume":"129","author":"Z Hijazi","year":"2014","unstructured":"Hijazi Z, Hohnloser SH, Oldgren J et al (2014) Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (randomized evaluation of long-term anticoagulation therapy) trial analysis. Circulation 129:961\u2013970","journal-title":"Circulation"},{"key":"1446_CR69","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1093\/eurheartj\/ehs274","volume":"33","author":"SH Hohnloser","year":"2012","unstructured":"Hohnloser SH, Hijazi Z, Thomas L et al (2012) Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 33:2821\u20132830","journal-title":"Eur Heart J"},{"key":"1446_CR70","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1161\/CIRCULATIONAHA.111.055970","volume":"125","author":"SH Hohnloser","year":"2012","unstructured":"Hohnloser SH, Oldgren J, Yang S et al (2012) Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (randomized evaluation of long-term anticoagulation therapy) trial. Circulation 125:669\u2013676","journal-title":"Circulation"},{"key":"1446_CR71","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2165\/00003088-198611060-00005","volume":"11","author":"NH Holford","year":"1986","unstructured":"Holford NH (1986) Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose\u2013effect relationship. Clin Pharmacokinet 11:483\u2013504","journal-title":"Clin Pharmacokinet"},{"key":"1446_CR72","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1161\/STROKEAHA.113.000990","volume":"44","author":"M Hori","year":"2013","unstructured":"Hori M, Connolly SJ, Zhu J et al (2013) Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke 44:1891\u20131896","journal-title":"Stroke"},{"key":"1446_CR73","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1253\/circj.CJ-12-0454","volume":"76","author":"M Hori","year":"2012","unstructured":"Hori M, Matsumoto M, Tanahashi N et al (2012) Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation\u2014the J-ROCKET AF study. Circ J 76:2104\u20132111","journal-title":"Circ J"},{"key":"1446_CR74","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","volume":"64","author":"CT January","year":"2014","unstructured":"January CT, Wann LS, Alpert JS et al (2014) 2014 AHA\/ACC\/HRS Guideline for the management of patients with atrial fibrillation: a report of the American college of cardiology\/american heart association task force on practice guidelines and the heart rhythm society. J Am Coll Cardiol 64:e1\u2013e76","journal-title":"J Am Coll Cardiol"},{"key":"1446_CR75","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s40273-014-0246-7","volume":"33","author":"A Janzic","year":"2015","unstructured":"Janzic A, Kos M (2015) Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control. Pharmacoeconomics 33:395\u2013408","journal-title":"Pharmacoeconomics"},{"key":"1446_CR76","doi-asserted-by":"crossref","first-page":"e63479","DOI":"10.1371\/journal.pone.0063479","volume":"8","author":"AK Kakkar","year":"2013","unstructured":"Kakkar AK, Mueller I, Bassand JP et al (2013) Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD Registry. PLoS One 8:e63479","journal-title":"PLoS One"},{"key":"1446_CR77","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1001\/archinte.167.3.229","volume":"167","author":"SE Kimmel","year":"2007","unstructured":"Kimmel SE, Chen Z, Price M et al (2007) The influence of patient adherence on anticoagulation control with warfarin: results from the International normalized ratio adherence and genetics (IN-RANGE) study. Arch Intern Med 167:229\u2013235","journal-title":"Arch Intern Med"},{"key":"1446_CR78","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/cpdd.26","volume":"2","author":"D Kubitza","year":"2013","unstructured":"Kubitza D, Becka M, Schwers S, Voith B (2013) Investigation of pharmacodynamic and pharmacokinetic interactions between rivaroxaban and enoxaparin in healthy male subjects. Clinical Pharm in Drug Dev 2:270\u2013277","journal-title":"Clinical Pharm in Drug Dev"},{"key":"1446_CR79","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s12325-015-0189-1","volume":"32","author":"F Lalibert\u00e9","year":"2015","unstructured":"Lalibert\u00e9 F, Cloutier M, Crivera C et al (2015) Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users. Adv Ther 32:216\u2013227","journal-title":"Adv Ther"},{"key":"1446_CR80","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1185\/03007995.2014.907140","volume":"30","author":"F Lalibert\u00e9","year":"2014","unstructured":"Lalibert\u00e9 F, Cloutier M, Nelson WW et al (2014) Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Curr Med Res Opin 30:1317\u20131325","journal-title":"Curr Med Res Opin"},{"key":"1446_CR81","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3810\/hp.2014.08.1114","volume":"42","author":"F Lalibert\u00e9","year":"2014","unstructured":"Lalibert\u00e9 F, Pilon D, Raut MK et al (2014) Hospital length of stay of nonvalvular atrial fibrillation patients who were administered rivaroxaban versus warfarin with and without pretreatment parenteral anticoagulants therapies. Hosp Pract (1995) 42:17\u201325","journal-title":"Hosp Pract (1995)"},{"key":"1446_CR82","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1185\/03007995.2013.867843","volume":"30","author":"F Lalibert\u00e9","year":"2014","unstructured":"Lalibert\u00e9 F, Pilon D, Raut MK et al (2014) Hospital length of stay: is rivaroxaban associated with shorter inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation? Curr Med Res Opin 30:645\u2013653","journal-title":"Curr Med Res Opin"},{"key":"1446_CR83","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1161\/01.STR.32.2.392","volume":"32","author":"M Lamassa","year":"2001","unstructured":"Lamassa M, Di Carlo A, Pracucci G et al (2001) Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project). Stroke 32:392\u2013398","journal-title":"Stroke"},{"key":"1446_CR84","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1097\/ALN.0b013e3181895bd8","volume":"109","author":"JH Levy","year":"2008","unstructured":"Levy JH, Tanaka KA, Dietrich W (2008) Perioperative hemostatic management of patients treated with vitamin K antagonists. Anesthesiology 109:918\u2013926","journal-title":"Anesthesiology"},{"key":"1446_CR85","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1136\/bmj.325.7371.1022","volume":"325","author":"GYH Lip","year":"2002","unstructured":"Lip GYH, Hart RG, Conway DSG (2002) Antithrombotic therapy for atrial fibrillation. Br Med J 325:1022\u20131025","journal-title":"Br Med J"},{"key":"1446_CR86","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/eurheartj\/eht428","volume":"35","author":"KW Mahaffey","year":"2014","unstructured":"Mahaffey KW, Stevens SR, White HD et al (2014) Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. Eur Heart J 35:233\u2013241","journal-title":"Eur Heart J"},{"key":"1446_CR87","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/CIRCHEARTFAILURE.112.000143","volume":"6","author":"JJ McMurray","year":"2013","unstructured":"McMurray JJ, Ezekowitz JA, Lewis BS et al (2013) Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial. Circ Heart Fail 6:451\u2013460","journal-title":"Circ Heart Fail"},{"key":"1446_CR88","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1477-9560-12-14","volume":"12","author":"ES Mearns","year":"2014","unstructured":"Mearns ES, White CM, Kohn CG et al (2014) Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression. Thromb J 12:14","journal-title":"Thromb J"},{"key":"1446_CR89","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/j.1365-2125.2012.04409.x","volume":"75","author":"J Mendell","year":"2013","unstructured":"Mendell J, Noveck RJ, Shi M (2013) A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin. Br J Clin Pharmacol 75:966\u2013978","journal-title":"Br J Clin Pharmacol"},{"key":"1446_CR90","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1160\/TH15-02-0116","volume":"114","author":"F Michalski","year":"2015","unstructured":"Michalski F, Tittl L, Werth S et al (2015) Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry. Thromb Haemost 114:1076\u20131084","journal-title":"Thromb Haemost"},{"key":"1446_CR91","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1477-9560-12-5","volume":"12","author":"M Molteni","year":"2014","unstructured":"Molteni M, Cimminiello C (2014) Warfarin and atrial fibrillation: from ideal to real the warfarin affaire. Thromb J 12:5","journal-title":"Thromb J"},{"key":"1446_CR92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","volume":"53","author":"W Mueck","year":"2014","unstructured":"Mueck W, Stampfuss J, Kubitza D, Becka M (2014) Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet 53:1\u201316","journal-title":"Clin Pharmacokinet"},{"key":"1446_CR93","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/europace\/eun369","volume":"11","author":"M Nabauer","year":"2009","unstructured":"Nabauer M, Gerth A, Limbourg T et al (2009) The registry of the German competence NETwork on atrial fibrillation: patient characteristics and initial management. Europace 11:423\u2013434","journal-title":"Europace"},{"key":"1446_CR94","unstructured":"National Institute for Health and Care Excellence (2014) Atrial fibrillation: management. NICE Clinical guideline 180. https:\/\/www.nice.org.uk\/guidance\/cg180 . Accessed 21 Sept 2016"},{"key":"1446_CR95","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1185\/03007995.2014.933577","volume":"30","author":"WW Nelson","year":"2014","unstructured":"Nelson WW, Song X, Coleman CI et al (2014) Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation. Curr Med Res Opin 30:2461\u20132469","journal-title":"Curr Med Res Opin"},{"key":"1446_CR96","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1185\/03007995.2015.1074064","volume":"31","author":"WW Nelson","year":"2015","unstructured":"Nelson WW, Song X, Thomson E et al (2015) Medication persistence and discontinuation of rivaroxaban and dabigatran etexilate among patients with non-valvular atrial fibrillation. Curr Med Res Opin 31:1831\u20131840","journal-title":"Curr Med Res Opin"},{"key":"1446_CR97","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1093\/eurheartj\/ehi505","volume":"26","author":"R Nieuwlaat","year":"2005","unstructured":"Nieuwlaat R, Capucci A, Camm AJ et al (2005) Atrial fibrillation management: a prospective survey in ESC member countries: the Euro heart survey on atrial fibrillation. Eur Heart J 26:2422\u20132434","journal-title":"Eur Heart J"},{"key":"1446_CR98","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ahj.2014.07.002","volume":"168","author":"EC O\u2019Brien","year":"2014","unstructured":"O\u2019Brien EC, Simon DN, Allen LA et al (2014) Reasons for warfarin discontinuation in the outcomes registry for better informed treatment of atrial fibrillation (ORBIT-AF). Am Heart J 168:487\u2013494","journal-title":"Am Heart J"},{"key":"1446_CR99","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1105594","volume":"367","author":"JB Olesen","year":"2012","unstructured":"Olesen JB, Lip GYH, Kamper AL et al (2012) Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 367:625\u2013635","journal-title":"N Engl J Med"},{"key":"1446_CR100","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","volume":"353","author":"L Osterberg","year":"2005","unstructured":"Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353:487\u2013497","journal-title":"N Engl J Med"},{"key":"1446_CR101","doi-asserted-by":"crossref","first-page":"300","DOI":"10.2165\/00003088-199630040-00003","volume":"30","author":"G Palareti","year":"1996","unstructured":"Palareti G, Legnani C (1996) Warfarin withdrawal. Pharmacokinetic-pharmacodynamic considerations. Clin Pharmacokinet 30:300\u2013313","journal-title":"Clin Pharmacokinet"},{"key":"1446_CR102","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883\u2013891","journal-title":"N Engl J Med"},{"key":"1446_CR103","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1160\/TH03-08-0541","volume":"91","author":"C Perret-Guillaume","year":"2004","unstructured":"Perret-Guillaume C, Wahl DG (2004) Low-dose warfarin in atrial fibrillation leads to more thromboembolic events without reducing major bleeding when compared to adjusted-dose\u2014a meta-analysis. Thromb Haemost 91:394\u2013402","journal-title":"Thromb Haemost"},{"key":"1446_CR104","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1160\/TH15-03-0192","volume":"114","author":"CV Pollack Jr","year":"2015","unstructured":"Pollack CV Jr, Reilly PA, Bernstein R et al (2015) Design and rationale for RE-VERSE AD: a phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost 114:198\u2013205","journal-title":"Thromb Haemost"},{"key":"1446_CR105","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","volume":"373","author":"CV Pollack Jr","year":"2015","unstructured":"Pollack CV Jr, Reilly PA, Eikelboom J et al (2015) Idarucizumab for dabigatran reversal. N Engl J Med 373:511\u2013520","journal-title":"N Engl J Med"},{"key":"1446_CR106","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF03188828","volume":"19","author":"J Popovic","year":"1994","unstructured":"Popovic J, Mikov M, Jakovljevic V (1994) Pharmacokinetic analysis of a new acenocoumarol tablet formulation during a bioequivalence study. Eur J Drug Metab Pharmacokinet 19:85\u201389","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"1446_CR107","unstructured":"Portola Pharmaceuticals (2014) Portola Pharmaceuticals announces commercial supply agreement for andexanet alfa with Lonza. http:\/\/investors.portola.com\/phoenix.zhtml?c=198136&p=irol-newsroomArticle&ID=1978716 . Accessed 21 Sept 2016"},{"key":"1446_CR108","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacc.2013.07.104","volume":"63","author":"PA Reilly","year":"2014","unstructured":"Reilly PA, Lehr T, Haertter S et al (2014) The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY trial (randomized evaluation of long-term anticoagulation therapy). J Am Coll Cardiol 63:321\u2013328","journal-title":"J Am Coll Cardiol"},{"key":"1446_CR109","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E et al (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383:955\u2013962","journal-title":"Lancet"},{"key":"1446_CR110","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1056\/NEJMoa1313600","volume":"370","author":"T Sanna","year":"2014","unstructured":"Sanna T, Diener HC, Passman RS et al (2014) Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 370:2478\u20132486","journal-title":"N Engl J Med"},{"key":"1446_CR111","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1161\/CIRCULATIONAHA.113.002283","volume":"128","author":"R Sarode","year":"2013","unstructured":"Sarode R, Milling TJ, Jr., Refaai MA et al (2013) Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation 128:1234\u20131243","journal-title":"Circulation"},{"key":"1446_CR112","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1161\/CIRCULATIONAHA.111.029801","volume":"124","author":"RC Seet","year":"2011","unstructured":"Seet RC, Friedman PA, Rabinstein AA (2011) Prolonged rhythm monitoring for the detection of occult paroxysmal atrial fibrillation in ischemic stroke of unknown cause. Circulation 124:477\u2013486","journal-title":"Circulation"},{"key":"1446_CR113","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa1510991","volume":"373","author":"DM Siegal","year":"2015","unstructured":"Siegal DM, Curnutte JT, Connolly SJ et al (2015) Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 373:2413\u20132424","journal-title":"N Engl J Med"},{"key":"1446_CR114","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.cjca.2012.01.021","volume":"28","author":"AC Skanes","year":"2012","unstructured":"Skanes AC, Healey JS, Cairns JA et al (2012) Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate\/rhythm control. Can J Cardiol 28:125\u2013136","journal-title":"Can J Cardiol"},{"key":"1446_CR115","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2146\/ajhp110203","volume":"69","author":"X Song","year":"2012","unstructured":"Song X, Sander SD, Johnson BH, Varker H, Amin AN (2012) Impact of atrial fibrillation and oral anticoagulation on hospital costs and length of stay. Am J Health Syst Pharm 69:329\u2013338","journal-title":"Am J Health Syst Pharm"},{"key":"1446_CR116","doi-asserted-by":"crossref","first-page":"e002758","DOI":"10.1136\/bmjopen-2013-002758","volume":"3","author":"R S\u00f8rensen","year":"2013","unstructured":"S\u00f8rensen R, Gislason G, Torp-Pedersen C et al (2013) Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. BMJ Open 3:e002758","journal-title":"BMJ Open"},{"key":"1446_CR117","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/clc.22373","volume":"38","author":"S Tamayo","year":"2015","unstructured":"Tamayo S, Peacock FW, Patel M et al (2015) Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27 467 patients taking rivaroxaban. Clin Cardiol 38:63\u201368","journal-title":"Clin Cardiol"},{"issue":"2","key":"1446_CR118","first-page":"130","volume":"13","author":"H Cate ten","year":"2015","unstructured":"ten Cate H, Haas S, Accetta G et al (2015) Quality of vitamin K antagonist control and 1-year outcomes: a global perspective from the GARFIELD-AF registry. J Thromb Haemost 13(suppl 2):130 (abstract OR096)","journal-title":"J Thromb Haemost"},{"key":"1446_CR119","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.2165\/00003088-200544120-00003","volume":"44","author":"M Ufer","year":"2005","unstructured":"Ufer M (2005) Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet 44:1227\u20131246","journal-title":"Clin Pharmacokinet"},{"key":"1446_CR120","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1161\/CIRCHEARTFAILURE.113.000212","volume":"6","author":"S Diepen van","year":"2013","unstructured":"van Diepen S, Hellkamp AS, Patel MR et al (2013) Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF. Circ Heart Fail 6:740\u2013747","journal-title":"Circ Heart Fail"},{"key":"1446_CR121","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1160\/TH15-06-0453","volume":"114","author":"TC Villines","year":"2015","unstructured":"Villines TC, Schnee J, Fraeman K et al (2015) A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system. Thromb Haemost 114:1290\u20131298","journal-title":"Thromb Haemost"},{"key":"1446_CR122","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archinte.167.3.239","volume":"167","author":"HD White","year":"2007","unstructured":"White HD, Gruber M, Feyzi J et al (2007) Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 167:239\u2013245","journal-title":"Arch Intern Med"},{"key":"1446_CR123","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","volume":"22","author":"PA Wolf","year":"1991","unstructured":"Wolf PA, Abbott RD, Kannel WB (1991) Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 22:983\u2013988","journal-title":"Stroke"},{"key":"1446_CR124","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-154-8-201104190-00004","volume":"154","author":"V Yank","year":"2011","unstructured":"Yank V, Tuohy CV, Logan AC et al (2011) Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med 154:529\u2013540","journal-title":"Ann Intern Med"},{"key":"1446_CR125","doi-asserted-by":"crossref","first-page":"e531S","DOI":"10.1378\/chest.11-2304","volume":"141","author":"JJ You","year":"2012","unstructured":"You JJ, Singer DE, Howard PA et al (2012) Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 141:e531S\u2013e575S","journal-title":"Chest"},{"key":"1446_CR126","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1161\/CIRCOUTCOMES.113.000192","volume":"6","author":"M Zalesak","year":"2013","unstructured":"Zalesak M, Siu K, Francis K et al (2013) Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. Circ Cardiovasc Qual Outcomes 6:567\u2013574","journal-title":"Circ Cardiovasc Qual Outcomes"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-016-1446-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11239-016-1446-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-016-1446-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T01:17:29Z","timestamp":1568596649000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11239-016-1446-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,28]]},"references-count":126,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["1446"],"URL":"https:\/\/doi.org\/10.1007\/s11239-016-1446-0","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,28]]}}}